94 completed, 23 terminated, 13 recruiting, 10 unknown. 94 Phase 2, 70 Phase 1, 6 Not applicable, 6 Phase 3, 5 Phase 4.
Follow plerixafor: new trials by email Literature Review of plerixafor trials Research Report on plerixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders Filgrastim, Plerixafor, Leukapheresis - Bone Marrow Failure Syndrome | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 12 | 2026-11-01 | 2026-10-06 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-21 | 2026-10-27 |
| Mozobil for Autologous Hematopoietic Stem Cell Transplantation Plerixafor, Gcsf - Multiple Myeloma, Hodgkin Lymphoma | Phase 2 | Recruiting | Thomas Jefferson University | 100 | 2025-10-16 | 2025-11-28 |
| Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy Plerixafor, Filgrastim, Palifermin - X-linked Severe Combined Immunodeficiency, X-SCID | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 18 | 2025-05-09 | 2026-10-13 |
| Gene Editing For Sickle Cell Disease Plerixafor, Busulfan, Gene-modified CD34+ cells - Sickle Cell Disease | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 25 | 2025-03-21 | 2026-10-15 |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML Rabbit Anti thymocyte globulin, Busulfan, Fludarabine - AML, Childhood, Aml | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 68 | 2024-11-15 | 2026-08-24 |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma Elranatamab, Lenalidomide, Plerixafor - Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-17 | 2026-08-10 |
| Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor - RUNX1 Familial Platelet Disorder | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 4 | 2024-05-20 | 2026-06-11 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells - Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2024-04-17 | 2026-08-13 |
| Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium Plerixafor - Asherman Syndrome, Atrophic Endometrium | Early Phase 1 | Recruiting | Hugh Taylor | 90 | 2023-11-01 | 2025-11-12 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor Plerixafor - Sickle Cell Disease | Phase 2 | Withdrawn | St. Jude Children's Research Hospital | 2023-04-01 | 2023-04-07 | |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-10-16 |
| Plerixafor for Poorly Mobilized Lymphoma Plerixafor,G-CSF - Lymphoma | Phase 4 | Unknown | Peking University | 140 | 2022-12-19 | 2023-03-13 |
| A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate - Osteosarcoma, Bone Metastases | Phase 1 | Withdrawn | Albert Einstein College of Medicine | 2022-08-01 | 2022-10-14 | |
| Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb) Plerixafor 20 MG/ML [Mozobil], Placebo - COVID-19 Acute Respiratory Distress Syndrome, COVID-19 | Phase 2 | Withdrawn | 4Living Biotech | 2022-07-19 | 2023-04-10 | |
| Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease MGTA-145, Plerixafor - Sickle Cell Disease | Phase 2 | Terminated | Ensoma | 1 | 2022-06-24 | 2025-07-25 |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
Showing 20 of 159. Sign in to see all of them.
Multiple Myeloma (38) · Lymphoma, Non-Hodgkin (32) · Leukemia, Myeloid, Acute (26) · Hodgkin Disease (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Lymphoma (12) · Myelodysplastic Syndromes (12) · Anemia, Sickle Cell (11) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Leukemia (6) · Neoplasms, Plasma Cell (6) · Fanconi Anemia (5) · Agammaglobulinemia (3) · Glioblastoma (3)
Genzyme, a Sanofi Company (26) · Washington University School of Medicine (13) · Fred Hutchinson Cancer Center (6) · M.D. Anderson Cancer Center (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · St. Jude Children's Research Hospital (6) · National Heart, Lung, and Blood Institute (NHLBI) (5) · City of Hope Medical Center (3) · Emory University (3) · Ensoma (3) · National Cancer Institute (NCI) (3) · Sanofi (3) · Weill Medical College of Cornell University (3) · Assistance Publique - Hôpitaux de Paris (2) · Case Comprehensive Cancer Center (2)
United States (113) · Canada (9) · France (6) · Italy (6) · Germany (5) · United Kingdom (5) · China (4) · Spain (4) · Belgium (2) · Israel (2) · Japan (2) · Mexico (2) · Russia (2) · Bulgaria (1) · Czechia (1)
Mark Schroeder, M.D. (3) · Richard W Childs, M.D. (3) · Suk S De Ravin, M.D. (3) · Akshay Sharma, MBBS (2) · David H McDermott, M.D. (2) · Geoffrey Uy, M.D. (2) · Hans-Peter Kiem (2) · John DiPersio, M.D., Ph.D. (2) · John F Tisdale, M.D. (2) · Lawrence Recht (2) · Leona Holmberg (2) · Mitchell Horwitz, MD (2) · Akshay Sharma, MBBS, MSc (1)
PMID 19720922, PMID 20067838, PMID 28292947, PMID 29410180, PMID 19135941, PMID 19167685, PMID 19363221, PMID 19483760, PMID 19597422, PMID 19929463, PMID 20530974, PMID 21835955, PMID 21890643, PMID 22308295, PMID 23474805, PMID 24244025, PMID 24523241, PMID 24723677, PMID 25105369, PMID 25804941, PMID 27118452, PMID 27535663, PMID 27846612, PMID 28067870, PMID 28718760, PMID 28797783, PMID 29392425, PMID 29419425, PMID 29472357, PMID 29550630, PMID 29724902, PMID 30043330, PMID 30654137, PMID 30890544, PMID 31352850, PMID 31456261, PMID 31501599, PMID 31618456, PMID 31940591, PMID 32127657, PMID 33956057, PMID 34160085, PMID 34166998, PMID 34175041, PMID 34398557, PMID 34485595, PMID 34515338, PMID 34538132, PMID 34751952, PMID 36163427
2014 (3), P30CA015704 (3), 2005 (1), 2009 (1), 2015 (1), P01CA247886 (1), P01HL053750 (1), P30CA033572 (1), P30CA043703 (1), P30CA124435 (1), P50CA107399 (1), R01CA163870 (1), R01HL081499 (1), R01HL116217 (1), R21CA143805 (1)